A New T-Cell activation assay based on Hyris qPCR Technology marks a disruptive approach for the detection of SARS-CoV-2 specific cellular immunity

A scientific paper recently published in Nature Biotechnology reveals new research regarding how we track and monitor T-cell patients' immunity to SARS-CoV-2, leveraging the unique characteristics of Hyris

Related Keywords

Italy ,London ,City Of ,United Kingdom ,Singapore ,Cristina Lapucci ,Kostenloser Wertpapierhandel ,Jordi Ochando ,Ernesto Guccione ,Antonio Bertoletti ,Megan Schwarz ,Professor Of Oncological Sciences ,Icahn School Of Medicine At Mount Sinai ,Icahn School Mount Sinai ,Pharmacological Sciences ,Nature Biotechnology ,Icahn School ,Mount Sinai ,Molecular Biology ,Stefano Lo Priore ,Oncological Sciences ,Icahn Mount ,Assistant Professor ,Cell Based Medicine ,Cell ,Activation ,Essay ,Ased ,Tyris ,Pcr ,Technology ,Parks ,Disruptive ,Approach ,Detection ,Cars ,Specific ,Ellular ,Immunity ,